Kidney cancer drug rejected by NICE19th April 2011
The National Institute for Health and Clinical Excellence has said the drug Everolimus, which treats kidney cancer, is too expensive to be used by the NHS.
The charity Kidney Cancer UK, which had set up an appeal against the draft guidelines, said it was not happy about the result.
Around 4,000 people are diagnosed every year with advanced renal cell carcinoma (kidney cancer).
NICE has approved two drugs to treat the disease, Sunitinib and Pazopanib. The drug Everolimus has been found to prolong life when these two drugs fail to work.
Everolimus, which is also known as Afinitor, comes at a cost of over £200,000 per patient for a full course of treatment.
Sir Andrew Dillon, NICE chief executive, said: "We regret not to be able to recommend this drug, but we have to ensure that the money available to the NHS, for treating cancer and other conditions is used to best effect, particularly when the NHS, like the rest of the public sector, is under considerable financial pressure."
Dr Pat Hanlon, from Kidney Cancer UK, said his response to the news was: "one of deep disappointment".
He added: "We know the NHS cannot afford all drugs, but they are effectively robbing people of a few months of life."
Share this page
Thursday 28th April 2011 @ 3:45
This makes me sad and angry. In the USA we have a whole group of different drugs available to treat RCC. Many work for a long time and its great that there are others to turn to when the 1st ones stops working. I hope that they reconsider this decisions.
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: Kidney cancer drug rejected by NICE
Author: Jess Laurence
Article Id: 18273
Date Added: 19th Apr 2011